Kristina Buder-Bakhaya

Kristina Buder-Bakhaya

Auto-generated profile, based on publicly available information

Kristina Buder-Bakhaya


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
KBKarolina Benesova
Karolina Benesova
CSCarsten Schulz
Carsten Schulz
HAHoda Anwar
Hoda Anwar
Antonia Dimitrakopoulou-StraussAntonia Dimitrakopoulou-Strauss
Antonia Dimitrakopoulou-Strauss
JHJessica C. Hassel
Jessica C. Hassel

1 February 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
SGSimone M. Goldinger
Simone M. Goldinger
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
SLSerigne N. Lo
Serigne N. Lo
AFAndrea Forschner
Andrea Forschner
MMMeredith McKean
Meredith McKean
AMAlexander M. Menzies
Alexander M. Menzies

8 February 2018 in OncoImmunology
Verified
Journal Article
Open access
MGMaria Rita Gaiser
Maria Rita Gaiser
CWCleo-Aron Weis
Cleo-Aron Weis
TGTimo Gaiser
Timo Gaiser
HJHong Jiang
Hong Jiang
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
IBIsaac Brownell
Isaac Brownell
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that responds to PD-1/PD-L1 immune checkpoint inhibitors. CD200 is another checkpoint modulator whose receptor is found on tumor-promoting myeloid cells, including M2 macrophages. We found high CD200 mRNA expression in MCC tumors, and CD200 immunostaining was demonstrated on 95.5% of MCC tumors. CD200R-expressing myeloid cells were present in the MCC tumor microenvironment. MCC-associated macrophages had a higher average CD163:CD68 staining ratio (2.67) than controls (1.13), indicating an immunosuppressive M2 phenotype. Accordingly, MCC tumors contained increased densities of FOXP3+ regulatory T-cells. Intravenous administration of blocking anti-CD200 antibody to MCC xenograft mice revealed specific targeting of drug to tumor. In conclusion, MCC are highly CD200 positive and associated with immunosuppressive M2 macrophages and regulatory T-cells. As anti-CD200 antibody effectively targets CD200 on MCC tumor cells in vivo, this treatment may provide a novel immunotherapy for MCC independent of PD-1/PD-L1 blockade.

13 October 2015 in Dermatology
Verified
Journal Article
Closed access
JLJulia Lengfeld
Julia Lengfeld
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
MGMatthias Goebeler
Matthias Goebeler
MWMarion Wobser
Marion Wobser
Oral bisphosphonates are widely used drugs for the treatment of various indications such as postmenopausal osteoporosis. Ulcerations of the upper gastrointestinal tract, predominantly reported for alendronate, are common side effects. The occurrence of ulcerations within the oral cavity is less well known and probably underreported. Especially in cases of incorrect mode of intake, oral bisphosphonates are prone to induce oral ulcerations by as yet incompletely delineated mechanisms. We herein report on 2 elderly female patients suffering from oral ulcerations, which could be attributed to inadequate ingestion of alendronate. Possible ways to cause damage to the oral mucosa include non-specific toxic and pro-apoptotic effects, partly via bisphosphonate-mediated interference with intracellular signalling such as the mevalonate downstream pathway. Adequate patient advice in terms of correct use of oral bisphosphonates is crucial in order to prevent mucosal damage. Otherwise, prompt treatment cessation or a switch to an intravenously administered bisphosphonate is likely to achieve complete healing.

20 December 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
Jessica HasselJessica Hassel
Jessica Hassel
KBKristina Buder‐Bakhaya
Kristina Buder‐Bakhaya
CBCarolin Bender
Carolin Bender
LZLisa Zimmer
Lisa Zimmer
BWBenjamin Weide
Benjamin Weide
T(the German Dermatooncology Group (DeCOG/ADO)
the German Dermatooncology Group (DeCOG/ADO)
Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred and eighty patients with BRAF‐mutant metastatic melanoma who had progressed on treatment with single‐agent BRAFi from February 2010 to April 2015 were included in a retrospective data analysis focused on patterns of progression, treatment beyond progression (TBP) and subsequent treatments after BRAFi therapy. Analysis revealed that 51.1% of patients progressed with both new and existing metastases opposed to progression of only preexisting (28.3%) or only new (20.6%) metastases. Exclusive extracranial progression occurred in 50.6% of patients compared to both extra‐ and intracranial (29.4%) or sole cerebral progression (20%). Multivariable analyses demonstrated that single site progression and primary response to BRAFi were associated with improved progression‐free survival. Progression with exclusively new or only existing metastases and a baseline Eastern Cooperative Oncology Group (ECOG) of 0 were associated with prolonged overall survival (OS). TBP had no significant impact on OS. Other subsequent treatments showed low efficacy with the exception of anti‐PD‐1 antibodies. In conclusion we identified specific patterns of progression which significantly correlate with further prognosis after progression on BRAFi treatment. In contrast to previously published data, we could not demonstrate a significant survival benefit for BRAFi TBP. Subsequent therapies had strikingly low efficacy except for PD‐1 inhibitors.

16 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MSMartin Salzmann
Martin Salzmann
KBKarolina Benesova
Karolina Benesova
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
DPDimitris Papamichail
Dimitris Papamichail
Antonia Dimitrakopoulou-StraussAntonia Dimitrakopoulou-Strauss
Antonia Dimitrakopoulou-Strauss
Jessica HasselJessica Hassel
Jessica Hassel
Introduction: BRAF inhibitors (BRAFi), commonly used in BRAF-mutated metastatic melanoma (MM) treatment, frequently cause arthralgia. Although this is one of the most common side effects, it has not been characterized yet. Methods: We retrospectively included all patients treated with BRAFi +/− MEK inhibitors (MEKi) for MM at the National Center for Tumor Diseases (Heidelberg) between 2010 and 2018 and reviewed patient charts for the occurrence and management of arthralgia. The evaluation was supplemented by an analysis of frozen sera. Results: We included 154 patients (63% males); 31% (48/154) of them reported arthralgia with a median onset of 21 days after the start of the therapy. Arthralgia mostly affected small joints (27/36, 75%) and less frequently large joints (19/36, 53%). The most commonly affected joints were in fingers (19/36, 53%), wrists (16/36, 44%), and knees (12/36, 33%). In 67% (24/36) of the patients, arthralgia occurred with a symmetrical polyarthritis, mainly of small joints, resembling the pattern typically observed in patients affected by rheumatoid arthritis (RA), for which a role of the MAPK signaling pathway was previously described. Patients were negative for antinuclear antibodies, anti-citrullinated protein antibodies, and rheumatoid factor; arthritis was visible in 10 of 13 available PET–CT scans. The development of arthralgia was linked to better progression-free survival and overall survival. Conclusion: Arthralgia is a common side effect in patients receiving BRAFi +/− MEKi therapy and often presents a clinical pattern similar to that observed in RA patients. Its occurrence was associated with longer-lasting tumor control.